| Accession |
PRJCA022013 |
| Title |
CheckMate 8HW: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 8HW |
| Relevance |
Medical |
| Data types |
Biomaker
|
| Organisms |
Homo sapiens
|
| Description |
A Phase 3 Randomized Clinical Trial of Nivolumab alone, Nivolumab in Combination with Ipilimumab, or Investigator's Choice Chemotherapy in Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic Colorectal Cancer |
| Sample scope |
Multiisolate |
| Release date |
2023-12-13 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| Bristol-Myers Squibb (China) Investment Co., Ltd., Bristol-Myers Squibb Company
|
|
JXSL1900097/JXSL1900098
|
|
|
|
| Submitter |
Li
Jin (lijin@csco.org.cn)
|
| Organization |
Shanghai East Hospital |
| Submission date |
2023-12-13 |
